The hemophilia market is expected to experience significant growth due to advancements in gene therapy, innovative treatments, and an increasing focus on personalized medicine. Rising awareness and ...
CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating ...
CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...
CSL Behring has shared positive four-year results from a late-stage study of its haemophilia B gene therapy Hemgenix ...
The study shows that 94% of patients eliminated factor IX prophylaxis and maintained near-normal factor IX levels through ...
Data from the study showed that HEMGENIX continues to deliver sustained factor IX activity levels for up to four years post-treatment. The treatment also provides long-term bleed protection, ...
Exposing Adenoviruses: Inder Verma and colleagues used nude mice to study immune system and humoral responses during gene therapy. Y. Dai, E.M. Schwartz, D. Gu, W.-W ...
Four years after receiving Hemgenix in a Phase 3 trial, bleeding rates and the use of replacement therapy are low for men ...
The adeno-associated virus (AAV) vector-based therapy is given as a one-shot intravenous infusion, delivering a gene for Factor IX, a clotting factor that is deficient in haemophilia B.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback